new molecules and indications for glp 1 medicines GLP-1 GLP-1 Market Trends and Global

Results: From randomization to year 1, liraglutide 3.0 mg recipients lost 5.8 kg (95% confidence interval 3.78.0) more weight than those on placebo and 3.8 kg (1.66.0) more than those on orlistat ( P 0.0001

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Capristo E, Panunzi S, De Gaetano A, Spuntarelli V, Bellantone R, Giustacchini P, Birkenfeld AL, Amiel S, Bornstein SR, Raffaelli M, Mingrone G

Monitoring body composition with tools like bioimpedance can also help identify significant losses in muscle or bone mass, which may signal the need for intervention

Acknowledgements None to given at this time